Delta-8 THC

Delta-8-Tetrahydrocannabinol (Delta-8 THC) is a naturally occurring cannabinoid found in cannabis in very small concentrations, typically less than 0.1% of the plant's total cannabinoid content. It is an isomer of Delta-9 THC, differing only in the position of a double bond on the carbon chain — at the 8th carbon rather than the 9th. This seemingly minor structural difference results in notably reduced psychoactive potency, estimated at roughly 50-75% of Delta-9 THC's strength. Users commonly describe Delta-8's effects as a 'lighter' or 'smoother' version of traditional THC, with less anxiety and paranoia.

Delta-8 THC became a major commercial phenomenon beginning in 2020-2021, as manufacturers discovered methods to convert hemp-derived CBD into Delta-8 THC through acid-catalyzed isomerization. This process allowed companies to produce psychoactive products that arguably fell within the legal definition of hemp under the 2018 Farm Bill, which defined hemp as cannabis containing less than 0.3% Delta-9 THC. The resulting Delta-8 market grew rapidly to an estimated $2 billion in annual sales, though regulatory challenges have since resulted in bans or restrictions in approximately 20 states.

The safety and quality of commercially produced Delta-8 THC products have been subjects of concern. The chemical conversion process from CBD to Delta-8 can produce unknown byproducts if not properly purified, and the largely unregulated market has led to products with inconsistent potency, residual solvents, and in some cases, harmful contaminants. The FDA has issued consumer warnings about Delta-8 THC products, citing adverse event reports and lack of regulatory oversight.